Clinical trials: Graft Patency
Systemic Juvenile Idiopathic Arthritis
Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA
This was a phase III study designed to provide efficacy and safety data for canakinumab administered for at least 48 weeks as subcutaneous (s.c.) injection every 4 weeks (q4wk) in Japanese patients with Systemic Juvenile…
- Trial name
- NCT02396212
- Testing
- Canakinumab
- Where
- 7 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B Virus Infection, Children
Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B
This study aims to evaluate the efficacy and safety of entecavir monotherapy versus sequential entecavir plus pegylated interferon α-2b in achieving functional cure in immune-active, HBeAg-positive children aged 3-6 years with…
- Conditions
- Hepatitis B Virus Infection, Children, Chronic Hepatitis B
- Trial name
- NCT07345611
- Testing
- Entecavir, Entecavir + Pegylated interferon α-2b
- Volunteers
- 60 people
- Sponsor
- Qing-Lei Zeng
Wounds and Injuries, Wound Infection
Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
This study will evaluate the use of free autologous dermal fat grafting (also called free dermal fat autografting) to treat complex craniofacial wounds that have failed standard treatment and to understand how well these grafts…
- Conditions
- Wounds and Injuries, Wound Infection, Facial Bones Fracture, Soft Tissue Injuries
- Trial name
- FTFDT2 (NCT03880188)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dufresne, Craig, MD, PC
CMV Viremia, Immunosuppression-related Infectious Disease
Virus-specific Activated T Lymphocytes From a Donor in Hematopoietic Progenitor Transplanted Patients
Marrow transplanted immunocompromised patients with cytomegalovirus (CMV) viral infection will be treated with CMV activated T-Lymphocytes. T-Lymphocytes will be obtained through an apheresis from a compatible donor.
- Trial name
- NCT04018261
- Testing
- Activated T-Lymphocytes
- Where
- 7 sites in Spain
- Volunteers
- 26 people
- Sponsor
- Banc de Sang i Teixits
Vascular Trauma, Arterial Injury
An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury.
The goal of this study is to assess the safety and efficacy of Symvess in sexually mature adolescents (17 years of age or younger) who require a vascular conduit to repair an extremity arterial injury when autologous vein graft…
- Conditions
- Vascular Trauma, Arterial Injury, Arterial Bleeding
- Trial name
- NCT07762313
- Testing
- Acellular Tissue Engineered Vessel (Symvess)
- Volunteers
- 10 people
- Sponsor
- Humacyte, Inc.
Resistant Chronic GVHD
Alefacept for Chronic Graft Versus Host Disease
Alefacept (AMEVIVE®) is an immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fcof IgG1.
- Trial name
- NCT00397332
- Testing
- Alefacept
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Hadassah Medical Organization
Wounds and Injuries, Burns
Treatment of Wounds With a New Adhesive Foam Dressing
This study will look at whether ELECT, a new adhesive foam dressing, can offer an alternative to traditional wound care methods. Patients will be treated with ELECT for 14 days.
- Trial name
- NCT02807584
- Testing
- ELECT
- Where
- South Africa
- Volunteers
- 25 people
- Sponsor
- Smith & Nephew, Inc.
Chronic Graft-Versus-Host Disease
Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells
Chronic Graft-versus-Host Disease (cGvHD) is a potentially lethal disorder. A variety of second line immunosuppressive agents have been investigated but no optimal treatment has emerged.
- Trial name
- MSC-cGvHD (NCT02291770)
- Testing
- Mesenchymal Stromal Cells
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Guangdong Provincial People's Hospital
Ischemic Heart Disease, Atherosclerosis
Graft Patency as a Predictor of Health-related Quality of Life.
The health-related quality of life questionnaire "EQ-5D" has been collected in connection with several interventional and observational studies where the no-touch vein harvesting technique in CABG has been used.
- Trial name
- NCT02547194
- Where
- Sweden
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- Örebro County Council
Chronic Graft-versus-host-disease
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
This study will be conducted to compare Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy.
- Trial name
- NCT06821542
- Testing
- INCA034176, Best Available Therapy (BAT)
- Where
- 130 sites in Austria, Belgium and 14 more
- Volunteers
- 9 people
- Sponsor
- Incyte Corporation
Chronic Graft Versus Host Disease
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
This is an open-label, single group, Phase 1/2, 1-arm study for treatment of children aged 1 to <18 years with active moderate-to-severe cGVHD that is refractory to or recurred after at least 2 prior lines of systemic therapy for…
- Trial name
- schoolROCK (NCT07116031)
- Testing
- Belumosudil
- Where
- 35 sites in United States, Belgium and 11 more
- Volunteers
- 37 people
- Sponsor
- Sanofi
Chronic Graft-versus-host-disease, Leukemia Relapse
A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT
In this study, a randomized, prospective, multicenter, open cohort study was conducted to investigate patients with acute leukemia (14～60-year-old) with different ATG doses (10 mg / kg and 12.5 mg / kg ) in fludarabine, busulfan…
- Trial name
- NCT03190733
- Testing
- ATG
- Volunteers
- 192 people
- Sponsor
- Zhujiang Hospital
Acute Graft Versus Host Disease
Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD
To determine a safe and effective dose of pentostatin in steroid-refractory aGvHD and to identify the minimal effective dose of pentostatin defined as the lowest dose that produces a response in 20% or more of patients while…
- Trial name
- NCT00032773
- Testing
- pentostatin for injection
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Steroid-Refractory Acute Graft Versus Host Disease
T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)
The study is designed as an open-label, single arm Phase III, multicenter trial to evaluate the efficacy and safety of T-Guard treatment in patients with Steroid-Refractory acute Graft versus Host Disease (SR-aGVHD).
- Trial name
- 1802 (NCT04128319)
- Testing
- T-Guard
- Where
- 24 sites in United States
- Volunteers
- 3 people
- Sponsor
- Xenikos
Graft vs Host Disease
Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease
The purpose of this Phase I/II, open-label, dose-escalation study is to evaluate an investigational monoclonal antibody administered as a first-line therapy to patients with acute, Grade II, III, or IV graft-versus-host disease…
- Trial name
- NCT00032292
- Testing
- Visilizumab
- Where
- 7 sites in United States
- Volunteers
- 34 people
- Sponsor
- Facet Biotech
Steroid Refractory GVHD
Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease
This study is a Open Label Prospective Dose-Ranging Escalation and Expansion Trial to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Dosing, and Efficacy of RLS-0071 for the secondary treatment of acute…
- Trial name
- AURORA (NCT06343792)
- Testing
- RLS-0071
- Where
- 11 sites in United States, Germany and 1 more
- Volunteers
- 66 people
- Sponsor
- ReAlta Life Sciences, Inc.
Steroid-Refractory Acute Graft-Versus-Host Disease, Acute Graft-Versus-Host Disease
Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
This study is a prospective, multicenter, open-label, phase II clinical trial designed to evaluate the safety and efficacy of moxibustion in patients with steroid-refractory acute graft-versus-host disease (SR-aGVHD) following…
- Conditions
- Steroid-Refractory Acute Graft-Versus-Host Disease, Acute Graft-Versus-Host Disease, Graft-Versus-Host Disease, Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- NCT07572669
- Testing
- Moxibustion, Moxibustion Twice Daily Plus Best Available Treatment (BID Group), Best Available Treatment (BAT)
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Graft-versus-host Disease (GVHD)
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).
- Trial name
- NCT03112603
- Testing
- Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX)
- Where
- 191 sites in United States, Australia and 29 more
- Volunteers
- 330 people
- Sponsor
- Incyte Corporation
Kidney Diseases
Steroid Withdrawal in Pediatric Renal Transplant Recipients Under Cyclosporine (CyA) and Mycophenolate Mofetil (MMF)
The present study investigates the safety and efficacy of steroid withdrawal in pediatric renal transplant recipients with stable graft function under concomitant immunosuppression with cyclosporine and mycophenolate mofetil.
- Trial name
- NCT00309218
- Testing
- methylprednisolone
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Klinik für Kinder- und Jugendmedizin
Kidney Transplantation, Transplantation Immunology
A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients
The purpose of this study is to compare the efficacy and safety of Prograf extended release(XL) plus MMF with Prograf plus MMF in de novo kidney transplant recipients.
- Conditions
- Kidney Transplantation, Transplantation Immunology, Host vs Graft Reaction
- Trial name
- NCT00717678
- Testing
- Prograf-XL, Prograf, MMF
- Where
- 5 sites in Taiwan
- Volunteers
- 73 people
- Sponsor
- Astellas Pharma Inc